New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.
Data will be presented on BARACLUDE® (entecavir) in patients with chronic hepatitis B, and on two compounds in early clinical development for the treatment of hepatitis C -- BMS-650032, an NS3 inhibitor, and PEG-Interferon lambda, a novel type 3 interferon. The presentation of data on BMS-650032 will mark the first public disclosure of information about this investigational compound. Data will also be presented on the investigational compound brivanib, the first selective dual inhibitor of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) signaling, which is in Phase 3 development for the treatment of hepatocellular carcinoma.
“The data on Bristol-Myers Squibb compounds that will be presented at AASLD demonstrate the breadth of our research and development portfolio and support the company’s goal of developing innovative medicines for patients with various diseases of the liver,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. “Our established expertise in viral hepatitis and oncology uniquely position Bristol-Myers Squibb to be at the forefront of delivering innovation in the treatment of multiple types and stages of liver disease. We are proud to be releasing new data on our significant portfolio of assets.”
AI algorithm accurately detects early-stage metabolic-associated steatotic liver disease